Please login to the form below

Not currently logged in
Email:
Password:

Stuart Collinson joins Silence Therapeutics

He replaces Simon Sturge as non-executive director

Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.

The move follows Simon Sturge's resignation as non-executive director of the biotechnology company as he seeks to focus on his other business commitments.

Dr Collinson has held senior management roles in public and private life science companies across Europe and the US, including at GlaxoWellcome, now GlaxoSmithKline, Baxter International and Cabrellis Pharmaceuticals, now part of Celgene.

He is a partner of US-based VC firm Forward Ventures and currently also serves as chairman and chief executive officer of Tioga Pharmaceuticals and director for both Arcturus Therapeutics and Essentialis.

Chief executive officer of Silence Therapeutics Ali Mortazavi said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

21st January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics